Compare Eli Lilly And Co (LLY) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard International High Dividend Yield ETF — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Vanguard International High Dividend Yield ETF trades at $101.05 (market cap $22.80B). The key difference: Eli Lilly And Co is far larger — about 45.6× Vanguard International High Dividend Yield ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| LLY | VYMI | |
|---|---|---|
Market Cap | $1.04T | $22.80B |
Volume | 3,064,878 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $107.13 |
52-Week Low | $799.57 | $82.92 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
VYMI trades at $100.66, up 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF focuses on international high dividend yield stocks, with recent institutional buying activity from Envestnet and Corient Private Wealth. Recent news highlights strong performance with a 29% one-year return and 14.13% five-year average annual return, supported by financials, energy, and healthcare sector exposure.
The outlook remains positive given Vanguard's bullish stance on international developed markets and the ETF's attractive dividend yield. Key risks include global economic volatility and currency fluctuations, but institutional accumulation and sector alignment with rising rates support the investment thesis for income-focused investors seeking international diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
